Welcome to our dedicated page for Redhill Biopharm news (Ticker: RDHL), a resource for investors and traders seeking the latest updates and insights on Redhill Biopharm stock.
RedHill Biopharma Ltd (NASDAQ: RDHL) is a specialty biopharmaceutical leader focused on gastrointestinal and infectious disease therapies. This page provides investors and industry professionals with comprehensive updates on the company’s clinical developments, regulatory milestones, and strategic initiatives.
Access real-time announcements including FDA submissions, clinical trial results, and partnership agreements. Track progress across RedHill’s commercial products like Talicia for H. pylori and Aemcolo for travelers’ diarrhea, along with late-stage candidates such as opaganib in oncology and inflammatory diseases.
Our curated news collection enables informed decision-making by consolidating material events including earnings reports, intellectual property updates, and research collaborations. Content spans therapeutic area breakthroughs, management commentary, and market expansion activities.
Bookmark this page for streamlined access to verified RedHill Biopharma updates. Check regularly for developments impacting the company’s position in gastrointestinal therapeutics and pandemic preparedness research.
RedHill Biopharma Ltd (Nasdaq: RDHL) announced a firm commitment underwriting agreement with H.C. Wainwright & Co. for the sale of 1,250,000 American Depositary Shares (ADSs) at $8.00 each, with gross proceeds expected to reach $10 million. The closing is anticipated on or around March 4, 2021, subject to customary conditions. Additionally, there is a 30-day option for the underwriter to purchase up to 187,500 additional ADSs. Proceeds will be used for clinical development, commercialization, and general corporate purposes.
RedHill Biopharma (Nasdaq: RDHL) announced the expansion of its global Phase 2/3 study for opaganib, targeting severe COVID-19, to the U.S. The move follows FDA recommendations after reviewing Phase 2 data. The study, with 464 patients planned across 8 countries, is over 50% enrolled and expected to provide top-line data in Q2 2021. Preliminary results indicate opaganib significantly reduced oxygen requirements and demonstrated a robust safety profile in its Phase 2 study. Opaganib, a novel oral SK2 inhibitor, shows promise against viral variants and additional oncological applications.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has entered into manufacturing agreements with Cosmo Pharmaceuticals NV to produce Movantik and RHB-204. Movantik is RedHill's top-selling drug in the U.S., designed to treat opioid-induced constipation. RHB-204 is in Phase 3 trials for pulmonary nontuberculous mycobacteria disease, showing significant market potential estimated at over $500 million. The partnership is aimed at enhancing supply chain capabilities and meeting increasing market demands.
RedHill Biopharma (Nasdaq: RDHL) announced new manufacturing agreements with Cosmo Pharmaceuticals for two products: Movantik® and RHB-204. Movantik is RedHill's top-selling product for treating opioid-induced constipation, which affects millions. RHB-204 is in Phase 3 trials as a treatment for pulmonary nontuberculous mycobacterial disease, with market potential exceeding $500 million. These agreements enhance RedHill's supply capabilities and support ongoing strategic collaboration with Cosmo.
RedHill Biopharma Ltd. (Nasdaq: RDHL) has announced the dosing of its first patient in a U.S. Phase 2/3 study for RHB-107 (upamostat), aimed at treating symptomatic COVID-19 patients who do not require hospitalization. RHB-107, a potent serine protease inhibitor, demonstrated strong antiviral action against SARS-CoV-2 in preclinical studies. The trial includes 310 patients and utilizes innovative telemetry and home-based monitoring for safety and efficacy, intending to provide effective treatment against emerging viral variants.
On February 17, 2021, RedHill Biopharma Ltd. (Nasdaq: RDHL) announced the dosing of the first patient in its U.S. Phase 2/3 study of RHB-107 (upamostat), targeting symptomatic COVID-19 patients who do not require hospitalization. This investigational drug aims to inhibit viral entry by targeting serine proteases. The study will enroll 310 patients and utilizes innovative home monitoring to enhance safety. RedHill also advances its second COVID-19 candidate, opaganib, for hospitalized patients, with promising efficacy data already reported.
On February 9, 2021, RedHill Biopharma (Nasdaq: RDHL) announced its participation in two key virtual conferences: the SVB Leerink 10th Annual Global Healthcare Conference (Feb 22-26) and the BIO CEO & Investor Digital Conference (Feb 16-18). Dror Ben-Asher, CEO, will present on February 25, while Guy Goldberg, Chief Business Officer, will feature a session on-demand starting February 16. The presentations will be available for 30 days on RedHill's website. The company focuses on gastrointestinal and infectious diseases, with several late-stage clinical programs underway.
RedHill Biopharma Ltd. (Nasdaq: RDHL) will present at two upcoming virtual conferences: the SVB Leerink 10th Annual Global Healthcare Conference from February 22-26, 2021, with a presentation by CEO Dror Ben-Asher on February 25, and the BIO CEO & Investor Digital Conference from February 16-18, 2021, featuring Guy Goldberg, Chief Business Officer. Webcasts will be available for 30 days on RedHill's website. The company focuses on gastrointestinal and infectious diseases, highlighting drugs like Movantik, Talicia, and Aemcolo.
RedHill Biopharma (Nasdaq: RDHL) announced a positive recommendation from the independent Data Safety Monitoring Board (DSMB) to continue its global Phase 2/3 study of opaganib for severe COVID-19, based on a pre-scheduled review of efficacy and safety data. Opaganib has shown potential against viral resistance and has demonstrated improvements in reducing oxygen needs in patients. The study will expand to around 460 patients across 30 sites in 7 countries, with top-line data expected in Q2 2021 and potential emergency use applications.
RedHill Biopharma (Nasdaq: RDHL) has partnered with Cosmo Pharmaceuticals to expand manufacturing capacity for opaganib (Yeliva®), targeting increased demand following potential global emergency use authorizations. Opaganib is a novel SK2 inhibitor aimed at treating COVID-19 pneumonia and has demonstrated efficacy against viral strains. An interim analysis of a Phase 2/3 study is imminent, with promising preliminary safety and efficacy data reported from an earlier Phase 2 trial. The drug holds Orphan Drug designation from the FDA for cholangiocarcinoma.